FIG 3.

Efficacy of delayed BCX4430 administration initiated after virus challenge. Data represent the effects of time of BCX4430 treatment initiation on survival (A), mean percent weight change between 3 and 6 dpi (B), serum ALT (6 dpi) (C), liver virus titer (D), and serum virus titer (E) during a YFV infection in a hamster model. Treatments with BCX4430 (200 mg/kg/day) and ribavirin (50 mg/kg/day) were administered i.p. BID for 7 days, starting at the indicated time relative to virus challenge. Liver and serum samples were collected for assay from animals sacrificed at 4 dpi whose treatments began 4 h before virus challenge. The dashed lines in panels D and E represent the limits of detection. ***, P < 0.001, and **, P < 0.01, compared with vehicle treatment.